Exosomics Siena’s novel technology enables an exosome-based diagnostic solution development for liquid biopsy screening. Its range of molecular diagnostic original equipment manufacturer solutions provides its customers the ability to formulate the best quality of analytical assays with the highest sensitivity and specificity for prognosis, screening, and monitoring. With the detection of Warburgian tumor biomarkers through isolation and characterization of tumor-derived exosomes, Exosomics Siena’s technology allows early cancer diagnosis and treatment decisions to improve survival rate. Due to its strong focus on radically changing and developing a new class of liquid biopsy assays, and an aim to design a pan-cancer screening test to detect cancer in asymptomatic patients, Exosomics Siena earns Frost & Sullivan’s 2018 Europe Enabling Technology Leadership Award in the exosome-based liquid biopsy market.
Incremento fatturato Italia
Incremento fatturato estero
Generazione di occupazione
Aumento occupazione (inteso come numero di assunzioni)